GANX Gain Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819411 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.3%
TTM EPS YoY31.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-223.9%
ROA-148.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.3%
Debt / equity0.03x
Current ratio5.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.42M | $2.14M | $2.76M | $2.35M | $2.85M | $2.76M | $2.26M | $1.22M |
| SG&A expense | $1.78M | $2.54M | $2.59M | $2.12M | $1.94M | $2.33M | $2.11M | $2.11M |
| Operating income | -$3.20M | -$4.68M | -$5.35M | -$4.47M | -$4.79M | -$5.09M | -$4.37M | -$3.33M |
| Pretax income | -$3.09M | -$4.57M | -$5.43M | -$4.47M | -$4.74M | -$5.67M | -$4.43M | -$3.26M |
| Income tax | $72,489 | $104,070 | $183,066 | $70,116 | $549,288 | $141,205 | $100,509 | $504,738 |
| Net income | -$3.16M | -$4.68M | -$5.61M | -$4.54M | -$5.28M | -$5.81M | -$4.53M | -$3.77M |
| EBITDA | -$3.20M | -$4.67M | -$5.33M | -$4.44M | -$4.78M | -$5.08M | -$4.35M | -$3.31M |
| EPS (basic) | -0.07 | -0.11 | -0.13 | — | -0.15 | -0.19 | -0.16 | — |
| EPS (diluted) | -0.07 | -0.11 | -0.13 | — | -0.15 | -0.19 | -0.16 | — |
| Weighted avg. shares (diluted) | 43.77M | 42.88M | 42.23M | — | 35.00M | 30.34M | 28.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.70M | $13.08M | $16.54M | $20.84M | $8.84M | $6.73M | $9.10M | $10.42M |
| Current assets | $12.70M | $14.97M | $18.22M | $22.24M | $10.52M | $9.31M | $11.15M | $11.60M |
| PP&E, net | $40,324 | $47,026 | $54,435 | $74,916 | $85,572 | $96,190 | $97,509 | $103,619 |
| Intangibles | $65,741 | — | — | $102,837 | — | — | — | — |
| Total assets | $13.23M | $15.42M | $18.74M | $22.82M | $10.97M | $9.83M | $11.62M | $12.12M |
| Current liabilities | $2.37M | $3.43M | $3.89M | $3.35M | $4.17M | $5.20M | $5.03M | $3.91M |
| Short-term debt | $119,656 | $123,628 | $100,281 | $100,869 | $125,545 | $126,108 | $113,121 | $110,177 |
| Long-term debt | $189,056 | $220,058 | $273,265 | $300,084 | $298,797 | $325,359 | $314,476 | $328,327 |
| Total debt | $308,712 | $343,686 | $373,546 | $400,953 | $424,342 | $451,467 | $427,597 | $438,504 |
| Total liabilities | $3.08M | $4.13M | $4.73M | $4.25M | $5.06M | $6.14M | $5.84M | $4.78M |
| Shareholders' equity | $10.15M | $11.29M | $14.01M | $18.56M | $5.91M | $3.70M | $5.78M | $7.34M |
| Net debt | -$11.39M | -$12.74M | -$16.17M | -$20.44M | -$8.42M | -$6.28M | -$8.68M | -$9.98M |
| Shares outstanding | 44.32M | 43.34M | 42.49M | 42.07M | 35.98M | 30.77M | 28.75M | 27.13M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.05M | -$4.68M | -$4.73M | -$4.62M | -$4.93M | -$5.10M | -$3.82M | -$3.45M |
| Capital expenditure | — | — | — | — | — | — | — | $945 |
| Free cash flow | — | — | — | — | — | — | — | -$3.46M |
| Investing cash flow | — | — | — | — | — | — | — | -$43,447 |
| Financing cash flow | $1.75M | $1.37M | $404,321 | $16.55M | $7.03M | $2.47M | $2.40M | $2.31M |
| Depreciation & amortization | $7,000 | $15,000 | $21,303 | $28,241 | $10,000 | $10,000 | $20,660 | $21,307 |
| Stock-based compensation | $375,649 | $566,049 | $403,509 | $401,667 | $460,005 | $522,019 | $419,504 | $359,329 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.